可切除非小细胞肺癌的五蛋白预后特征改善TNM分期预后效能
该研究基于三个独立回顾性队列(117、96、105例)开发并验证了由五种蛋白免疫组化构成的预后特征。预后指数(PI)是DFS和OS的独立显著预测因子,并在外部多机构队列中得到验证。PI与IASLC第八版TNM分期互补,联合模型可改善风险分层。
要点
- 五蛋白预后指数是DFS和OS的独立显著预测因子
- PI在外部队列中验证了DFS和OS的预后价值
- PI与TNM第八版分期互补,联合模型改善风险分层
核心结论
- 研究识别并验证了一种临床可行的蛋白预后模型,可补充更新版TNM系统,实现更准确的风险分层。
研究设计与样本
- 三个独立回顾性肺鳞癌队列,分别117、96、105例,按IASLC第八版(2018)分期。
- 基于五种蛋白的免疫组化开发并验证预后特征。
主要发现
- PI是DFS的独立显著预测因子(p<0.001;HR=4.06,95%CI 2.18-7.56)。
- PI是OS的独立显著预测因子(p=0.004;HR=2.38,95%CI 1.32-4.31)。
- 外部队列验证PI对DFS(p=0.042;HR=2.01,95%CI 1.03-3.94)和OS(p=0.031;HR=2.29,95%CI 1.08-4.86)的预后价值。
- 包含分子与解剖(TNM)标准的联合模型在两个队列中均改善风险分层(p<0.05)。
临床怎么用
- 该五蛋白预后特征可作为补充TNM分期的工具,辅助评估早期肺鳞癌复发或死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Prognostic biomarkers have been very elusive in the lung squamous cell carcinoma (SCC) and none is currently being used in the clinical setting. We aimed to identify and validate the clinical utility of a protein-based prognostic signature to stratify patients with early lung SCC according to their risk of recurrence or death. METHODS: Patients were staged following the new International Association for the Study of Lung Cancer (IASLC) staging criteria (eighth edition, 2018). Three independent retrospective cohorts of 117, 96 and 105 patients with lung SCC were analysed to develop and validate a prognostic signature based on immunohistochemistry for five proteins. RESULTS: We identified a five protein-based signature whose prognostic index (PI) was an independent and significant predictor of disease-free survival (DFS) (p<0.001; HR=4.06, 95% CI 2.18 to 7.56) and overall survival (OS) (p=0.004; HR=2.38, 95% CI 1.32 to 4.31). The prognostic capability of PI was confirmed in an external multi-institutional cohort for DFS (p=0.042; HR=2.01, 95% CI 1.03 to 3.94) and for OS (p=0.031; HR=2.29, 95% CI 1.08 to 4.86). Moreover, PI added complementary information to the newly established IASLC TNM 8th edition staging system. A combined prognostic model including both molecular and anatomical (TNM) criteria improved the risk stratification in both cohorts (p<0.05). CONCLUSION: We have identified and validated a clinically feasible protein-based prognostic model that complements the updated TNM system allowing more accurate risk stratification. This signature may be used as an advantageous tool to improve the clinical management of the patients, allowing the reduction of lung SCC mortality through a more accurate knowledge of the patient's potential outcome.
引用
- Martínez-Terroba E, Behrens C, Agorreta J, et al. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax. 2018. PMID: 30472670. doi:10.1136/thoraxjnl-2018-212194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。